巨星醫療(02393.HK)收購德潤利嘉未達溢利保證 賣方不同意補償
巨星醫療控股(02393.HK)就有關收購深圳市德潤利嘉70%股本權益的溢利保證一事公布,指德潤利嘉截至2019年12月31日止年度達到的實際純利少於年度保證溢利,故德潤利嘉賣方有責任根據股份轉讓協議,向買方補償及償付補償額約976萬元人民幣。根據先前相互協定,待德潤利嘉的業務營運回復正常並維持現金流穩健後,補償額乃透過扣減應或將向賣方支付的累計股息全數償付。
賣方不同意上述補償選項,而儘管公司透過與德潤利嘉賣方進行內部通訊及會議多番提醒,賣方亦未有提供償付補償額的替代方案。因此,集團至今仍未收到賣方任何補償額。
集團已進行內部討論及尋求有關可就補償額向賣方採取的法律行動的法律意見,將於2021年9月中在深圳國際仲裁院展開仲裁程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.